GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Price-to-Owner-Earnings

OKYO Pharma (OKYO Pharma) Price-to-Owner-Earnings : (As of Jun. 01, 2024)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Price-to-Owner-Earnings?

As of today (2024-06-01), OKYO Pharma's share price is $1.49. OKYO Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for OKYO Pharma's Price-to-Owner-Earnings or its related term are showing as below:


OKYO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-01), OKYO Pharma's share price is $1.49. OKYO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.16. Therefore, OKYO Pharma's PE Ratio for today is At Loss.

As of today (2024-06-01), OKYO Pharma's share price is $1.49. OKYO Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.16. Therefore, OKYO Pharma's PE Ratio without NRI for today is At Loss.


OKYO Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for OKYO Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Price-to-Owner-Earnings Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OKYO Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, OKYO Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OKYO Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Price-to-Owner-Earnings falls into.



OKYO Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

OKYO Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.49/-0.42
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OKYO Pharma  (NAS:OKYO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


OKYO Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


OKYO Pharma (OKYO Pharma) Business Description

Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA